for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zai Lab Ltd

ZLAB.OQ

Latest Trade

34.97USD

Change

0.16(+0.46%)

Volume

5,995

Today's Range

34.38

 - 

35.23

52 Week Range

14.29

 - 

38.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
34.81
Open
34.60
Volume
5,995
3M AVG Volume
3.53
Today's High
35.23
Today's Low
34.38
52 Week High
38.31
52 Week Low
14.29
Shares Out (MIL)
58.11
Market Cap (MIL)
1,786.27
Forward P/E
-13.16
Dividend (Yield %)
--

Latest Developments

More

Zai Lab Announces Publication Of Pharmacokinetic Study Of Niraparib In Chinese Ovarian Cancer Patients

Incyte And Zai Lab Announce Collaboration And License Agreement For Incmga0012 In Greater China

Deciphera And Zai Lab Announce Exclusive License Agreement For Ripretinib In Greater China

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zai Lab Ltd

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Industry

Biotechnology & Drugs

Contact Info

4560 Jinke Road, Bldg. 1, 4F, Pudong

+86.21.61632588

http://www.zailaboratory.com/

Key Stats

1.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.320

2018

-2.640

2019(E)

-2.590
Price To Earnings (TTM)
--
Price To Sales (TTM)
13,798.95
Price To Book (MRQ)
7.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.45
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-56.44
Return on Equity (TTM)
-50.21

Latest News

BRIEF-Zai Lab Appoints Billy Cho As Chief Financial Officer

* ZAI LAB LIMITED APPOINTS BILLY CHO AS CHIEF FINANCIAL OFFICER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up